- Home
- DJCO vs ANAB Comparison
DJCO vs ANAB Comparison
Compare DJCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJCO | ANAB |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.5M | 1.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | DJCO | ANAB |
|---|---|---|
| Price | $514.56 | $49.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $59.90 |
| AVG Volume (30 Days) | 48.6K | ★ 442.1K |
| Earning Date | 12-18-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.36 | N/A |
| EPS | ★ 70.22 | N/A |
| Revenue | $79,159,000.00 | ★ $169,467,000.00 |
| Revenue This Year | N/A | $135.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.55 | ★ N/A |
| Revenue Growth | 10.54 | ★ 196.42 |
| 52 Week Low | $348.63 | $12.21 |
| 52 Week High | $596.60 | $51.43 |
Technical Indicators
Market Signals| Indicator | DJCO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 75.72 |
| Support Level | $512.15 | $43.92 |
| Resistance Level | $542.35 | $51.43 |
| Average True Range (ATR) | 20.30 | 2.22 |
| MACD | 0.34 | 0.22 |
| Stochastic Oscillator | 66.98 | 83.20 |
Price Performance
Historical ComparisonAbout DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).